This workshop is being held in conjunction with the
2009 AAPS Annual Meeting and Exposition.
Goals
Dissolution testing is a very important tool in drug development and quality control. Application of dissolution testing has widened to a variety of novel or special dosage forms and is referred as 'drug release' test. The test is used for the biopharmaceutical characterization of the drug product, and as a tool to assure consistent product (batch) quality within a defined set of specification criteria. Ideally, the drug release method should correlate with the in vivo performance of the product. However, because of the complexity of the novel dosage form and simplicity of in vitro release methodology, it may not be possible to achieve this. Nevertheless, the in vitro release methodology should serve to test the key performance of the formulation.
This workshop will present drug release methodologies to evaluate the product performance for special dosage forms, such as, buccal, topical, ophthalmic, inhalation, stent, and nanoparticle formulations. It will provide opportunities for the participants to interact with the faculty in panel discussions.
Special Announcements
-
Register by Sept. 11, 2009
and save!
Planning Committee Members
Cynthia K. Brown, Eli Lilly & Company, Co-chair
Horst-Dieter Friedel, Ph.D., Bayer HealthCare AG, Co-chair
Lucinda Buhse, Ph.D., U.S. Food and Drug Administration
Todd Cecil, Ph.D., United States Pharmacopeia (USP)
Susanne Kietel, Ph.D., EDQM
Johannes Kraemer, Ph.D., PHAST, Germany
J. Michael Morris, Ph.D., Irish Medicines Board, Ireland
Vinod P. Shah, Ph.D., International Pharmaceutical Federation (FIP) Scientific Secretary
Mary Stickelmeyer, Ph.D., Eli Lilly & Company
Chikoko Yamoto, Ph.D., National Institute of Health, Japan